Clinical Trial: NCT03534323
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-03-23 |
Study Overview
Brief Summary
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome
Official Title
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome
Intervention / Treatment
- Drug: Duvelisib
- Drug: Venetoclax
Other Study ID Numbers
- 18-089
Start Date (Actual)
2018-07-12
Primary Completion Date (Actual)
2024-12-01
Study Completion Date (Estimated)
2026-07-01
Enrollment (Actual)
55
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-03-23 |
Study Overview
Brief Summary
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome
Official Title
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome
Intervention / Treatment
- Drug: Duvelisib
- Drug: Venetoclax
Other Study ID Numbers
- 18-089
Start Date (Actual)
2018-07-12
Primary Completion Date (Actual)
2024-12-01
Study Completion Date (Estimated)
2026-07-01
Enrollment (Actual)
55
Study Type
Interventional
Phase
Phase 1, Phase 2